A preliminary study on the therapeutic efficacy of Duloxetine in the treatment of depersonalization-derealization disorder

doi:10.3969/j.issn.1006-7795.2023.04.012

Abstract

Abstract: Objective To explore the efficacy and influencing factors of Duloxetine in the treatment of depersonalization-derealization disorder (DPD). Methods The data were collected from January 2020 to December 2022 for DPD patients treated with Duloxetine at Beijing Anding Hospital, Capital Medical University. Survival analysis was used to analyze treatment efficacy and influencing factors. Results A total of 51 patients were included in this study, and 64.7% of the patients showed treatment efficacy. The median effective time was 118 (87, 643) days, and there was a trend of rapid improvement in emotional numbness symptoms. Education level was identified as a significant influencing factor for duloxetine treatment, with HR=0.81 (0.70, 0.95), P=0.008. Conclusions Duloxetine treatment for DPD, particularly for the patients with emotional numbness as the main complaint, has potential benefits and provides guidance for clinical treatment of DPD.

Key words: Duloxetine, depersonalization-derealization disorder, therapeutic efficacy

CLC Number:

Zheng Sisi, Song Mingkang, Song Nan, Zhu Hong, Jia Hongxiao. A preliminary study on the therapeutic efficacy of Duloxetine in the treatment of depersonalization-derealization disorder[J]. Journal of Capital Medical University, 2023, 44(4): 578-582.

References

［1］ Yang J Y, Millman L S M, David A S, et al. The prevalence of depersonalization-derealization disorder: a systematic review［J］. J Trauma Dissociation, 2023, 24(1): 8-41.
［2］ Michal M, Adler J, Wiltink J, et al. A case series of 223 patients with depersonalization-derealization syndrome［J］. BMC Psychiatry, 2016, 16: 203.
［3］ Simeon D, Knutelska M, Putnam F W, et al. Attention and memory in depersonalization-spectrum dissociative disorders: impact of selective-divided attentional condition, stimulus emotionality, and stress［J］. J Trauma Dissociation, 2023, 24(1): 42-62.
［4］徐蕊, 杨敬铭, 朱虹, 等. 人格解体障碍病人的自我面孔识别速度的研究［J］. 首都医科大学学报, 2017, 38(2): 192-196.
［5］贾竑晓, 徐蕊, 朱虹, 等. 人格解体障碍的自我认知损害的神经心理学研究进展［J］. 国际精神病学杂志, 2016, 43(1): 50-54.
［6］宋楠, 贾竑晓. 人格解体患者认知功能及与临床症状和社会功能的相关性［J］. 首都医科大学学报, 2020, 41(1): 59-63.
［7］ Hunter E C M, Charlton J, David A S. Depersonalisation and derealisation: assessment and management［J］. BMJ, 2017, 356: j745.
［8］ Sierra M. Depersonalization disorder: pharmacological approaches［J］. Expert Rev Neurother, 2008, 8(1): 19-26.
［9］ Simeon D, Guralnik O, Knutelska M, et al. Basal norepinephrine in depersonalization disorder［J］. Psychiatry Res, 2003, 121(1): 93-97.
［10］ American Psychiatric Association, American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5［M］. 5th ed. Washington, D.C.: American Psychiatric Association, 2013:302.
［11］ Jay E L, Sierra M, Van Den Eynde F, et al. Testing a neurobiological model of depersonalization disorder using repetitive transcranial magnetic stimulation［J］. Brain Stimul, 2014, 7(2): 252-259.
［12］ Simeon D, Kozin D S, Segal K, et al. De-constructing depersonalization: further evidence for symptom clusters［J］. Psychiatry Res, 2008, 157(1/3): 303-306.
［13］ Segal S K, Cahill L. Endogenous noradrenergic activation and memory for emotional material in men and women［J］. Psychoneuroendocrinology, 2009, 34(9): 1263-1271.
［14］ Montagrin A, Sander D. Emotional memory: from affective relevance to arousal［J］. Behav Brain Sci, 2016, 39: e216.
［15］ Segal S K, Stark S M, Kattan D, et al. Norepinephrine-mediated emotional arousal facilitates subsequent pattern separation［J］. Neurobiol Learn Mem, 2012, 97(4): 465-469.

[1]	Guo Yu, Chen Weiguan, Zhou Sanlian, Tang Liqiao, Sun Wangyan, Zhang Dongmei, Lu Hongjian. Correlation between serum glycoprotein non-metastatic melanoma protein B levels and disease severity and prognosis in patients with acute ischemic stroke [J]. Journal of Capital Medical University, 2025, 46(4): 702-709.
[2]	Jiang Chenguan, Liu Yan, Yang Zhou, Li Bingxin, Zhang Jianguo, Shi Lin. Research progress on the long-term effects of subthalamic nucleus deep brain stimulation on non-motor symptoms in Parkinson's disease [J]. Journal of Capital Medical University, 2025, 46(4): 733-741.
[3]	Huo Bixiu, Jia Hongxiao, , Ning Yanzhe, Zheng Sisi. Abnormal top-down and bottom-up attention patterns in patients suffering from coronary heart disease with heart qi deficiency syndrome [J]. Journal of Capital Medical University, 2025, 46(3): 455-462.
[4]	Xian Shulian, Jia Hongxiao, Li Xue, Wang Di, Song Mingkang, Yin Dongqing, Jiang Hairong. A study on the distribution patterns of traditional Chinese medicine syndrome types in antipsychotic-induced metabolic syndrome [J]. Journal of Capital Medical University, 2025, 46(3): 463-470.
[5]	Li Xue, Jia Hongxiao, Zhu Hong, Feng Zhengtian, Zheng Sisi, Wu Ziyao, Duan Yuhang. Research on core syndrome of generalized anxiety disorder in traditional Chinese medicine: based on network analysis method [J]. Journal of Capital Medical University, 2025, 46(3): 471-478.
[6]	Yin Dongqing, Jia Hongxiao, , Li Xue, Zheng Sisi, Ning Yanzhe. Qingre Jiedu recipe in the treatment of bipolar depression with the syndrome of internal stagnation of fire-heat: a randomized double-blind controlled trial [J]. Journal of Capital Medical University, 2025, 46(3): 479-486.
[7]	Li Yue, Chen Junyu, Chang Chunlei, Zhang Jing. Investigation on the mechanism of Huatan Anshen Decoction to improve neuronal apoptosis based on NLRP3/IL-18/NF-κB pathway [J]. Journal of Capital Medical University, 2025, 46(3): 487-495.
[8]	Huo Bixiu, Jia Hongxiao, , Ning Yanzhe. Research progress of cognitive function decline in patients with coronary heart disease [J]. Journal of Capital Medical University, 2025, 46(3): 496-502.
[9]	Ren Qianwei, Zhou Siyi, Jin Xinyue, Guo Fuzhen, Guan Zhongjun. Analysis of stroke-related risk factors among urban community residents: A case-control study based on propensity score matching [J]. Journal of Capital Medical University, 2025, 46(3): 520-526.
[10]	Wang Yongjun, Liu Tao, Liu Ziyang, Xiong Yunyun, Jing Jing, Xie Xuewei, Li Zixiao. The applications of artificial intelligence in the field of cerebrovascular diseases [J]. Journal of Capital Medical University, 2025, 46(2): 177-183.
[11]	Qi Han, Dong Chengcheng, Liu Rui, Zhu Xuequan, Lin Xuzhou, Qin Yanshu, Yu Zibo, Wang Haining, Li Lei, Feng Yuan, Zhang Ling, Yan Fang. Transition of body mass index and metabolic syndrome in patients with major depressive disorder [J]. Journal of Capital Medical University, 2025, 46(2): 202-209.
[12]	Li Qing, Zhao Xiaowen, Ren Jing, Yu Miao, Cui Hanfang, Ding Fangyuan, Liu Hao, Li Qiong, Wang Fan, Li Qing, Chen Xiyan, Lu Chengbiao, Li Shaomin, Zhao Jianhua. The correlation of serum hypoxia-inducible factor-1α level with cerebral microbleeds and cognitive impairment [J]. Journal of Capital Medical University, 2025, 46(2): 216-227.
[13]	Jing Jiao, Zhang Siyao, Liu Yanling, Wang Fen, Xiao Wei, Wang Zhenzhong. Effect of large artery atherosclerosis subtype on the efficacy of Ginkgo Diterpene Lactone Meglumine in acute ischemic stroke [J]. Journal of Capital Medical University, 2025, 46(2): 228-233.
[14]	Zi Xiaohui, Xia Xue, Li jing, Zhang Xiaoli, Zhou Quan, Wang Anxin, Wang Yilong. Advances in the application of antiplatelet therapy in intravenous thrombolysis for acute ischemic stroke patients [J]. Journal of Capital Medical University, 2025, 46(2): 234-242.
[15]	Wu Lin, Sun Junzhao, Han Chengchen, Nie Xingxing, Tian Yuhong, Pi Hongying. Observation of clinical effect of remote ischemic conditioning in patients with spontaneous intracerebral hemorrhage [J]. Journal of Capital Medical University, 2025, 46(2): 356-362.